TIANDA PHARMA issues profit warning, expects annual loss attributable to shareholders of no less than HKD 61 million
TIANDA PHARMA issued a profit warning, expecting an annual loss attributable to shareholders of no less than HKD 61 million for the year ending December 31, 2024, a significant increase from HKD 24.2 million in the same period of 2023. The main reasons for the increase in losses include a revenue decline of approximately 38% and a provision for goodwill impairment of HKD 1.3 million, the latter being non-recurring and non-cash in nature, which does not affect cash flow
According to the Zhitong Finance APP, TIANDA PHARMA (00455) announced that it expects the company's loss attributable to shareholders for the year ending December 31, 2024, to increase to no less than HKD 61 million, up from HKD 24.2 million for the year ending December 31, 2023. The increase in the loss attributable to shareholders is mainly due to: (1) the group's revenue for this fiscal year is expected to decline by approximately 38% compared to the previous year; and (2) a provision for goodwill impairment of HKD 1.3 million for this fiscal year (this impairment is non-recurring and non-cash in nature and will not affect the group's cash flow)
